1st Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

Firm
Client
Income
—
Expenses
$380,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Medicaid rare disease patient access to therapy; Medicaid line extension rebates; Expanded access - H.R. 909, the Andrea Sloan Compassionate Use Reform and Enhancement Act; Patent Reform - H.R. 9, Innovation Act; S. 632, STRONG Patents Act; Rare Pediatric Disease Priority Review Vouchers - H.R. 1537, Advancing Hope Act of 2015; DEA processes and re-exportation; FDA funding; Orphan Drug Tax Credit; Newborn Screening; Binge Eating Disorder awareness; ADHD awareness; Rare diseases awareness; FDA policies regarding wound care healing

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —
CARRIE BURKE New —
JOHN EDWARD GREISSING —
MARK LENKER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 1537 (114th), H.R. 909 (114th), H.R. 9 (114th), S. 632 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.